Abstract
Researchers at the University of Central Florida and the
University of Oklahoma have identified fungus-derived compounds for developing treatments
against drug-resistant species of Plasmodium. Compounds collected from a large library
of diverse fungi (including pure compounds and extracts) may enable scientists
to target new cellular structures of malaria-causing parasites such as Plasmodium
falciparum. The species is resistant to most antimalarial treatments, including
chloroquine.
Technical Details
The researchers identified potential antimalarial compounds
through cell-based screening of P. falciparum multidrug-resistant strains. The compounds
came from a diverse library of fungi found in habitats and ecological niches
across the United States. Using the SYBR Green I-based fluorescence assay, the
scientists screened the samples for agents with the ability to inhibit
intraerythrocytic growth of chloroquine-resistant P. falciparum Dd2. Such
agents were either an HDAC inhibitor or a peptaibol. These unique
pharmacophores from broad areas of chemical space provide chemical starting
points for developing lead compounds of new drugs against malaria.
Partnering Opportunity
The research team is looking for partners to develop the
technology further for commercialization.
Stage of Development
Preclinical.
Benefit
May alleviate the problem of drug resistance Could be used to act upon novel cellular targets May be used to treat or prevent one or more symptoms of malariaMarket Application
Drugs to treat malaria
Brochure
